ArticleTheranostics2020

The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by

Marion Chomet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.